nabumetone has been researched along with Arthritis, Degenerative in 66 studies
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee." | 9.09 | Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. ( Agrawal, NM; Ball, J; Bocanegra, TS; Caldwell, J; Dhadda, S; Hancock, L; Hurley, S; Kivitz, AJ; Weaver, AL, 1999) |
| "This 6-week study was conducted to test the efficacy, safety, and tolerability of rofecoxib (a selective COX-2 inhibitor) compared to nabumetone (a non-selective NSAID) and placebo in osteoarthritis (OA) patients aged 80 and older." | 9.09 | A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. ( Bolognese, J; DeTora, L; Ehrich, E; Ettinger, WH; Greenwald, M; Sperling, RS; Truitt, KE; Zeng, Q, 2001) |
| "We assessed the effects of nabumetone, sulindac, and placebo on renal function and renal excretion of vasodilatory prostaglandins in older female patients (age >50 years) with osteoarthritis and normal renal function." | 9.09 | Renal hemodynamic effects of nabumetone, sulindac, and placebo in patients with osteoarthritis. ( Cangiano, JL; Figueroa, J; Palmer, R, 1999) |
| "The results suggest that nabumetone was similar in efficacy by most criteria to diclofenac SR and piroxicam in relieving the symptoms of osteoarthritis; however, nabumetone's GI safety profile was generally superior to that of both comparator NSAIDs." | 9.09 | Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. ( Palmer, RH; Scott, DL, 2000) |
| "To conduct the first Canadian study of the comparative efficacy and safety of nabumetone and diclofenac SR in patients with primary osteoarthritis (OA) of the hip, knee and shoulder." | 9.08 | A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. ( Ahmad, S; Beaulieu, A; Bell, MJ; Bellamy, N; Bensen, WG; Davis, P; Khanna, VN; Kraag, GR; Lussier, A; Siminovitch, KA, 1995) |
| "Etodolac (Lodine) has been marketed in the United States since 1991 for managing pain and for acute and longterm treatment of the signs and symptoms of osteoarthritis (OA)." | 9.08 | Etodolac (Lodine) in the treatment of osteoarthritis: recent studies. ( Constantine, G; Schnitzer, TJ, 1997) |
| "The efficacy and safety of nabumetone are similar to those of aceclofenac in the treatment of knee osteoarthritis." | 9.08 | [Efficacy and safety of nabumetone in the treatment of knee osteoarthritis: a comparative clinical trial versus aceclofenac. Study Group of Nabumetone for Osteoarthritis of the Knee]. ( Gijón Baños, J, 1997) |
| "The efficacy of nabumetone was compared with that of diclofenac, naproxen, ibuprofen, and piroxicam in patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in a randomized, controlled, open-label, multicenter trial." | 9.07 | Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Lister, BJ; Poland, M, 1993) |
| "In a double blind, randomized, parallel group study, 197 patients with osteoarthritis (OA) received nabumetone (1000 mg/day) or indomethacin (75 mg/day) for 6 weeks and doses could be doubled." | 9.07 | Nabumetone compared with indomethacin in the treatment of osteoarthritis in general practice. ( Carle, WK; Kill, DC; Poland, M; Wade, AG, 1992) |
| "To study nabumetone (1,000 mg once daily) by comparison with piroxicam (20 mg once daily) in patients with osteoarthritis, a randomized, double-blind trial was set up in 40 general practices." | 9.07 | Randomized double-blind study of nabumetone and piroxicam in the treatment of osteoarthritis in Dutch general practice: efficacy and tolerability. ( De Bock, GH; Hermans, J; Mulder, JD, 1993) |
| "20 UK general-practice centres entered 243 patients into a 6-week double-blind, double-dummy, randomised, parallel-group trial designed to compare nabumetone 1 g at night with slow release diclofenac 100mg at night in the treatment of osteoarthritis." | 9.06 | A microcomputer-assisted study of nabumetone and slow release diclofenac in osteoarthritis. ( Fehilly, B; Laws, D; Saul, S, 1990) |
| "Following a washout period, one hundred six patients with osteoarthritis were randomly assigned single daily doses of either 1,000 mg of nabumetone or placebo given at bedtime as part of a six-week, controlled, double-blind study." | 9.06 | Nabumetone therapy of osteoarthritis. A six-week, placebo-controlled study. ( Blechman, WJ, 1987) |
| "A 6-month, double-blind, controlled, randomized, parallel study was performed to compare the efficacy and tolerance of nabumetone (1000 mg at bedtime) with naproxen (250 mg twice daily) in the treatment of osteoarthritis." | 9.06 | A 6-month, double-blind study comparing nabumetone to naproxen in the treatment of osteoarthritis. ( Goodman, LA; Pisko, EJ; Rice, D; Strader, K; White, R, 1987) |
| "The safety and efficacy of nabumetone (1,000 mg at bedtime) were compared with those of aspirin (900 mg four times daily) in the treatment of osteoarthritis in adult patients in a private practice setting as part of a six-month, double-blind, controlled, randomized, parallel group study." | 9.06 | Results of a six-month study comparing the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis. ( Mullen, BJ, 1987) |
| "The efficacy and safety of nabumetone (1,000 mg at bedtime) and naproxen (250 mg twice daily) were compared in a six-month, randomized, double-blind study of patients with osteoarthritis." | 9.06 | Nabumetone versus naproxen in the treatment of osteoarthritis. A six-month trial. ( Poiley, JE, 1987) |
| "This six-month, double-blind, controlled, randomized, parallel study at 13 medical centers compared the safety and efficacy of nabumetone (1,000 mg taken at bedtime) with that of naproxen (250 mg twice daily) in the treatment of osteoarthritis in symptomatic adult outpatients." | 9.06 | Six-month multi-center study comparing nabumetone with naproxen in the treatment of osteoarthritis. ( Bockow, BI; Box, P; Brodsky, AL; Burch, FX; Collins, RL; Fleischmann, RM; Keller, MI; Lipani, JA; Pisko, EJ; Poiley, JE, 1987) |
| "Nabumetone, belonging to a new class of anti-inflammatory drugs, was administered to 9 patients suffering from radiologically-confirmed osteoarthritis of one or more of the following articulations: knees, hips, cervical and lumbar spine." | 9.05 | Efficacy and safety of nabumetone in long-term treatment of osteoarthritis. ( Pintens, H; Verbruggen, LA, 1984) |
| " Nabumetone (Relafen), a new NSAID for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), may differ from the others." | 8.78 | Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis. ( Roth, SH, 1992) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 7.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "The incidence of lower extremity edema (LEE) AEs was generally similar between rofecoxib 12." | 7.71 | A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 7.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| "We evaluated the effectiveness and the tolerability of a new non steroidal antiinflammatory drug (NSAID), nabumetone (1 g/daily for at least 8 days), in 20 patients (10 males and 10 females), 4 with rheumatoid arthritis and 16 with osteoarthritis." | 7.68 | [Efficacy and tolerability of nabumetone in the treatment of painful symptomatology of rheumatoid arthritis and osteoarthrosis]. ( Iagnocco, A; Riccieri, V; Spadaro, A, 1991) |
| " The most common adverse effects that occurred were related to the gastrointestinal tract, nervous system, skin, and special senses." | 6.67 | Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. ( Fleischmann, RM, 1992) |
| "Naproxen-treated patients experienced significantly (p < 0." | 6.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| " Aspirin-treated patients experienced a greater frequency of withdrawal from the study because of adverse experiences (34 percent versus 13 percent), a greater incidence of having at least one treatment-related adverse experience (73 percent versus 52 percent), a greater percentage of patients with at least one moderate or severe treatment-related adverse experience (47 percent versus 22 percent), and a greater percentage of patients with treatment-related adverse experiences affecting the gastrointestinal system (43 percent versus 32 percent) or the inner ear (32 percent versus 10 percent)." | 6.66 | Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults. ( Appelrouth, DJ; Baim, S; Chang, RW; Cohen, MH; Englund, DW; Germain, BF; Hartman, SS; Jaffer, A; Mullen, BJ; Smith, FE, 1987) |
| "Nabumetone is a nonsteroidal anti-inflammatory prodrug, which exerts its pharmacological effects via the metabolite 6-methoxy-2-naphthylacetic acid (6-MNA)." | 6.42 | Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. ( Ekbom, A; Hedner, T; Samulesson, O; Ung, KA; Wadenvik, H; Währborg, P, 2004) |
| "We assessed the effects of nabumetone, sulindac, and placebo on renal function and renal excretion of vasodilatory prostaglandins in older female patients (age >50 years) with osteoarthritis and normal renal function." | 5.09 | Renal hemodynamic effects of nabumetone, sulindac, and placebo in patients with osteoarthritis. ( Cangiano, JL; Figueroa, J; Palmer, R, 1999) |
| ", Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee." | 5.09 | Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. ( Agrawal, NM; Ball, J; Bocanegra, TS; Caldwell, J; Dhadda, S; Hancock, L; Hurley, S; Kivitz, AJ; Weaver, AL, 1999) |
| "The results suggest that nabumetone was similar in efficacy by most criteria to diclofenac SR and piroxicam in relieving the symptoms of osteoarthritis; however, nabumetone's GI safety profile was generally superior to that of both comparator NSAIDs." | 5.09 | Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. ( Palmer, RH; Scott, DL, 2000) |
| "To evaluate the efficacy and gastrointestinal safety of nabumetone and diclofenac in the treatment of elderly patients with osteoarthritis, participating in a 3-month efficacy trial." | 5.09 | Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile. ( DeLapp, R; Kaine, J; Morgan , GJ; Palmer, R, 2001) |
| "This 6-week study was conducted to test the efficacy, safety, and tolerability of rofecoxib (a selective COX-2 inhibitor) compared to nabumetone (a non-selective NSAID) and placebo in osteoarthritis (OA) patients aged 80 and older." | 5.09 | A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. ( Bolognese, J; DeTora, L; Ehrich, E; Ettinger, WH; Greenwald, M; Sperling, RS; Truitt, KE; Zeng, Q, 2001) |
| "To conduct the first Canadian study of the comparative efficacy and safety of nabumetone and diclofenac SR in patients with primary osteoarthritis (OA) of the hip, knee and shoulder." | 5.08 | A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. ( Ahmad, S; Beaulieu, A; Bell, MJ; Bellamy, N; Bensen, WG; Davis, P; Khanna, VN; Kraag, GR; Lussier, A; Siminovitch, KA, 1995) |
| "Etodolac (Lodine) has been marketed in the United States since 1991 for managing pain and for acute and longterm treatment of the signs and symptoms of osteoarthritis (OA)." | 5.08 | Etodolac (Lodine) in the treatment of osteoarthritis: recent studies. ( Constantine, G; Schnitzer, TJ, 1997) |
| "The efficacy and safety of nabumetone are similar to those of aceclofenac in the treatment of knee osteoarthritis." | 5.08 | [Efficacy and safety of nabumetone in the treatment of knee osteoarthritis: a comparative clinical trial versus aceclofenac. Study Group of Nabumetone for Osteoarthritis of the Knee]. ( Gijón Baños, J, 1997) |
| "To compare the gastrointestinal safety, ulcerogenic potential, and clinical efficacy over 5 years of nabumetone and naproxen therapy, in patients with rheumatoid arthritis (RA) or osteoarthritis (OA)." | 5.07 | A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. ( Bennett, R; Caldron, P; Koepp, R; Mitchell, C; Roth, SH; Swenson, C, 1994) |
| "In a randomized, open-label, controlled, multicenter, 12-week study, the efficacy and safety of nabumetone (1,000-2,000 mg/day) versus diclofenac (100-200 mg/day), naproxen (500-1,500 mg/day), ibuprofen (1,200-3,200 mg/day), or piroxicam (10-20 mg/day) were evaluated in patients with osteoarthritis (OA) or rheumatoid arthritis (RA)." | 5.07 | Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. ( DeLapp, RE; Morgan, GJ; Poland, M, 1993) |
| "The efficacy of nabumetone was compared with that of diclofenac, naproxen, ibuprofen, and piroxicam in patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in a randomized, controlled, open-label, multicenter trial." | 5.07 | Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Lister, BJ; Poland, M, 1993) |
| "To study nabumetone (1,000 mg once daily) by comparison with piroxicam (20 mg once daily) in patients with osteoarthritis, a randomized, double-blind trial was set up in 40 general practices." | 5.07 | Randomized double-blind study of nabumetone and piroxicam in the treatment of osteoarthritis in Dutch general practice: efficacy and tolerability. ( De Bock, GH; Hermans, J; Mulder, JD, 1993) |
| "In a double blind, randomized, parallel group study, 197 patients with osteoarthritis (OA) received nabumetone (1000 mg/day) or indomethacin (75 mg/day) for 6 weeks and doses could be doubled." | 5.07 | Nabumetone compared with indomethacin in the treatment of osteoarthritis in general practice. ( Carle, WK; Kill, DC; Poland, M; Wade, AG, 1992) |
| "The efficacy and safety of nabumetone (1,000 mg at bedtime) and naproxen (250 mg twice daily) were compared in a six-month, randomized, double-blind study of patients with osteoarthritis." | 5.06 | Nabumetone versus naproxen in the treatment of osteoarthritis. A six-month trial. ( Poiley, JE, 1987) |
| "This six-month, double-blind, controlled, randomized, parallel study at 13 medical centers compared the safety and efficacy of nabumetone (1,000 mg taken at bedtime) with that of naproxen (250 mg twice daily) in the treatment of osteoarthritis in symptomatic adult outpatients." | 5.06 | Six-month multi-center study comparing nabumetone with naproxen in the treatment of osteoarthritis. ( Bockow, BI; Box, P; Brodsky, AL; Burch, FX; Collins, RL; Fleischmann, RM; Keller, MI; Lipani, JA; Pisko, EJ; Poiley, JE, 1987) |
| "20 UK general-practice centres entered 243 patients into a 6-week double-blind, double-dummy, randomised, parallel-group trial designed to compare nabumetone 1 g at night with slow release diclofenac 100mg at night in the treatment of osteoarthritis." | 5.06 | A microcomputer-assisted study of nabumetone and slow release diclofenac in osteoarthritis. ( Fehilly, B; Laws, D; Saul, S, 1990) |
| "A 6-month, double-blind, controlled, randomized, parallel study was performed to compare the efficacy and tolerance of nabumetone (1000 mg at bedtime) with naproxen (250 mg twice daily) in the treatment of osteoarthritis." | 5.06 | A 6-month, double-blind study comparing nabumetone to naproxen in the treatment of osteoarthritis. ( Goodman, LA; Pisko, EJ; Rice, D; Strader, K; White, R, 1987) |
| "A total of 1,924 persons (rheumatoid arthritis, 835; osteoarthritis, 1,073; volunteers, 16) received nabumetone in United States clinical trials." | 5.06 | Safety evaluation of nabumetone in United States clinical trials. ( Brindley, DA; Jackson, RE; Mitchell, FN, 1987) |
| "Following a washout period, one hundred six patients with osteoarthritis were randomly assigned single daily doses of either 1,000 mg of nabumetone or placebo given at bedtime as part of a six-week, controlled, double-blind study." | 5.06 | Nabumetone therapy of osteoarthritis. A six-week, placebo-controlled study. ( Blechman, WJ, 1987) |
| "The safety and efficacy of nabumetone (1,000 mg at bedtime) were compared with those of aspirin (900 mg four times daily) in the treatment of osteoarthritis in adult patients in a private practice setting as part of a six-month, double-blind, controlled, randomized, parallel group study." | 5.06 | Results of a six-month study comparing the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis. ( Mullen, BJ, 1987) |
| "Nabumetone, belonging to a new class of anti-inflammatory drugs, was administered to 9 patients suffering from radiologically-confirmed osteoarthritis of one or more of the following articulations: knees, hips, cervical and lumbar spine." | 5.05 | Efficacy and safety of nabumetone in long-term treatment of osteoarthritis. ( Pintens, H; Verbruggen, LA, 1984) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| " A MEDLINE search was conducted using the following indexing terms: antiinflammatory agents, nonsteroidal, nabumetone, rheumatoid arthritis (RA), and osteoarthritis (OA)." | 4.78 | Nabumetone: a "nonacidic" nonsteroidal antiinflammatory drug. ( Dahl, SL, 1993) |
| " Nabumetone (Relafen), a new NSAID for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), may differ from the others." | 4.78 | Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis. ( Roth, SH, 1992) |
| "Nabumetone is a new non-steroidal anti-inflammatory drug advocated for use in the symptomatic treatment of rheumatic and inflammatory conditions." | 3.76 | Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases. ( Friedel, HA; Todd, PA, 1988) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 3.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 3.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "The incidence of lower extremity edema (LEE) AEs was generally similar between rofecoxib 12." | 3.71 | A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002) |
| "To investigate recent national trends in nonsteroidal antiinflammatory drug (NSAID) and acetaminophen use for osteoarthritis (OA)." | 3.71 | Trends in medication use for osteoarthritis treatment. ( Ausiello, JC; Stafford, RS, 2002) |
| "We evaluated the effectiveness and the tolerability of a new non steroidal antiinflammatory drug (NSAID), nabumetone (1 g/daily for at least 8 days), in 20 patients (10 males and 10 females), 4 with rheumatoid arthritis and 16 with osteoarthritis." | 3.68 | [Efficacy and tolerability of nabumetone in the treatment of painful symptomatology of rheumatoid arthritis and osteoarthrosis]. ( Iagnocco, A; Riccieri, V; Spadaro, A, 1991) |
| "Osteoarthritis is a common disease of the cartilage in a joint for which the general practitioner (GP) is frequently consulted." | 2.68 | [Peripheral arthritis in family practice]. ( de Bock, GH, 1996) |
| " The most common adverse effects that occurred were related to the gastrointestinal tract, nervous system, skin, and special senses." | 2.67 | Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. ( Fleischmann, RM, 1992) |
| "Naproxen-treated patients experienced significantly (p < 0." | 2.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| "Two nabumetone-treated patients showed marked elevations in renal parameters, serum creatinine and blood urea nitrogen." | 2.67 | An overview of the long-term safety experience of nabumetone. ( Willkens, RF, 1990) |
| " By posttreatment endoscopy, nabumetone was significantly less toxic to the gastrointestinal tract than was naproxen." | 2.66 | Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy. ( Roth, SH, 1987) |
| " Aspirin-treated patients experienced a greater frequency of withdrawal from the study because of adverse experiences (34 percent versus 13 percent), a greater incidence of having at least one treatment-related adverse experience (73 percent versus 52 percent), a greater percentage of patients with at least one moderate or severe treatment-related adverse experience (47 percent versus 22 percent), and a greater percentage of patients with treatment-related adverse experiences affecting the gastrointestinal system (43 percent versus 32 percent) or the inner ear (32 percent versus 10 percent)." | 2.66 | Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults. ( Appelrouth, DJ; Baim, S; Chang, RW; Cohen, MH; Englund, DW; Germain, BF; Hartman, SS; Jaffer, A; Mullen, BJ; Smith, FE, 1987) |
| "Nabumetone is a nonsteroidal anti-inflammatory prodrug, which exerts its pharmacological effects via the metabolite 6-methoxy-2-naphthylacetic acid (6-MNA)." | 2.42 | Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. ( Ekbom, A; Hedner, T; Samulesson, O; Ung, KA; Wadenvik, H; Währborg, P, 2004) |
| " Although ketorolac, which is now available in oral form, is an effective analgesic, its long-term use is limited by a high incidence of gastrointestinal toxicity." | 2.39 | A review of selected newer nonsteroidal anti-inflammatory drugs. ( Amadio, P; Cummings, DM, 1994) |
| " The analysis proved that the principal component, adverse effect on work and daily activities as a result of emotional problems, was an independent factor related to the overall incidence of ADRs." | 1.32 | Adverse effect of drug-induced emotional problems on work and daily activities. A principal component as an independent predictor of ADRs in Shanghai patients with osteo-arthropathy taking nabumetone. ( Li, SL; Shi, W; Wang, YM; Yan, M, 2004) |
| "We have performed a detailed pharmacokinetic study of the plasma concentrations of the major active metabolite of nabumetone, 6-methoxy-2-naphthylacetic acid (6 MNA), attained after a single dose and during chronic administration comparing the results of a group of young healthy volunteers with those of a group of elderly arthritic patients." | 1.28 | A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients. ( Chellingsworth, MC; Jubb, R; Kendall, MJ; Kill, DC; Thawley, AR; Undre, NA, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (25.76) | 18.7374 |
| 1990's | 35 (53.03) | 18.2507 |
| 2000's | 14 (21.21) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, W | 3 |
| Wang, YM | 3 |
| Cheng, NN | 2 |
| Chen, BY | 2 |
| Li, D | 2 |
| Li, SL | 2 |
| Yan, M | 2 |
| Heyll, U | 1 |
| Hedner, T | 1 |
| Samulesson, O | 1 |
| Währborg, P | 1 |
| Wadenvik, H | 1 |
| Ung, KA | 1 |
| Ekbom, A | 1 |
| Wyplosz, B | 1 |
| Vautier, S | 1 |
| Lillo-Le Louët, A | 1 |
| Capron, L | 1 |
| Gillgrass, J | 1 |
| Grahame, R | 1 |
| Verbruggen, LA | 2 |
| Pintens, H | 2 |
| Ginsberg, F | 1 |
| Famaey, JP | 1 |
| Cytryn, E | 1 |
| Voss, GD | 1 |
| Schweitzer, P | 1 |
| Roth, SH | 4 |
| Bennett, R | 1 |
| Caldron, P | 1 |
| Mitchell, C | 1 |
| Swenson, C | 1 |
| Koepp, R | 1 |
| Helfgott, SM | 1 |
| Cummings, DM | 1 |
| Amadio, P | 1 |
| Tindall, EA | 1 |
| Jain, AK | 1 |
| McMahon, FG | 2 |
| April, PA | 1 |
| Bockow, BI | 2 |
| Cohen, SB | 1 |
| Fleischmann, RM | 3 |
| De Bock, GH | 3 |
| Hermans, J | 2 |
| Mulder, JD | 2 |
| Eversmeyer, W | 1 |
| Poland, M | 4 |
| DeLapp, RE | 3 |
| Jensen, CP | 1 |
| Morgan, GJ | 1 |
| Lister, BJ | 1 |
| Dahl, SL | 1 |
| Bellamy, N | 1 |
| Bensen, WG | 1 |
| Beaulieu, A | 1 |
| Siminovitch, KA | 1 |
| Kraag, GR | 1 |
| Lussier, A | 1 |
| Ahmad, S | 1 |
| Khanna, VN | 1 |
| Davis, P | 1 |
| Bell, MJ | 1 |
| van Marwijk, HW | 1 |
| Kaptein, AA | 1 |
| Schnitzer, TJ | 1 |
| Constantine, G | 1 |
| Nasonov, EL | 1 |
| Nasonova, SV | 1 |
| Gijón Baños, J | 1 |
| Hatoum, HT | 1 |
| Kong, SX | 1 |
| Cangiano, JL | 1 |
| Figueroa, J | 1 |
| Palmer, R | 2 |
| Agrawal, NM | 1 |
| Caldwell, J | 1 |
| Kivitz, AJ | 1 |
| Weaver, AL | 1 |
| Bocanegra, TS | 1 |
| Ball, J | 1 |
| Dhadda, S | 1 |
| Hurley, S | 1 |
| Hancock, L | 1 |
| Langman, MJ | 1 |
| Jensen, DM | 1 |
| Watson, DJ | 2 |
| Harper, SE | 2 |
| Zhao, PL | 2 |
| Quan, H | 1 |
| Bolognese, JA | 3 |
| Simon, TJ | 2 |
| Scott, DL | 1 |
| Palmer, RH | 1 |
| Morgan , GJ | 1 |
| Kaine, J | 1 |
| DeLapp, R | 1 |
| Truitt, KE | 1 |
| Sperling, RS | 3 |
| Ettinger, WH | 1 |
| Greenwald, M | 1 |
| DeTora, L | 1 |
| Zeng, Q | 1 |
| Bolognese, J | 1 |
| Ehrich, E | 1 |
| Reicin, AS | 1 |
| Shapiro, D | 1 |
| Barr, E | 1 |
| Yu, Q | 1 |
| Gertz, BJ | 1 |
| Krupa, D | 1 |
| Reicin, A | 1 |
| Ausiello, JC | 1 |
| Stafford, RS | 1 |
| Reitblat, T | 1 |
| Zamir, D | 1 |
| Estis, L | 1 |
| Priluk, R | 1 |
| Drogenikov, T | 1 |
| Viskoper, JR | 1 |
| Huskisson, EC | 1 |
| Irani, M | 1 |
| Fleischmann, R | 1 |
| Carle, WK | 1 |
| Wade, AG | 1 |
| Kill, DC | 2 |
| De Caterina, R | 1 |
| Giannessi, D | 1 |
| Lazzerini, G | 1 |
| Filipponi, P | 1 |
| Mannarelli, C | 1 |
| Vaiani, G | 3 |
| Grossi, E | 1 |
| Riccieri, V | 1 |
| Spadaro, A | 1 |
| Iagnocco, A | 1 |
| Laws, D | 1 |
| Saul, S | 1 |
| Fehilly, B | 1 |
| Willkens, RF | 1 |
| Stroehmann, I | 2 |
| Fedder, M | 2 |
| Zeidler, H | 1 |
| Cazzola, M | 1 |
| Montrone, F | 1 |
| Azzolini, V | 1 |
| Caruso, I | 1 |
| Visentini, R | 1 |
| Gottardo, R | 1 |
| Zampa, A | 1 |
| Sorbilli, G | 1 |
| Kendall, MJ | 1 |
| Chellingsworth, MC | 1 |
| Jubb, R | 1 |
| Thawley, AR | 1 |
| Undre, NA | 1 |
| Friedel, HA | 1 |
| Todd, PA | 1 |
| Pisko, EJ | 2 |
| Strader, K | 1 |
| Rice, D | 1 |
| White, R | 1 |
| Goodman, LA | 1 |
| Jenner, PN | 1 |
| Johnson, ES | 1 |
| Jackson, RE | 1 |
| Mitchell, FN | 1 |
| Brindley, DA | 1 |
| Blechman, WJ | 1 |
| Mullen, BJ | 2 |
| Appelrouth, DJ | 1 |
| Baim, S | 1 |
| Chang, RW | 1 |
| Cohen, MH | 1 |
| Englund, DW | 1 |
| Germain, BF | 1 |
| Hartman, SS | 1 |
| Jaffer, A | 1 |
| Smith, FE | 1 |
| Poiley, JE | 2 |
| Box, P | 1 |
| Brodsky, AL | 1 |
| Burch, FX | 1 |
| Collins, RL | 1 |
| Keller, MI | 1 |
| Lipani, JA | 1 |
| Vargas, R | 1 |
| Ryan, JR | 1 |
| Fitts, DA | 1 |
11 reviews available for nabumetone and Arthritis, Degenerative
| Article | Year |
|---|---|
[Meta-analysis on the effect and adverse reaction on patients with osteoarthritis and rheumatoid arthritis treated with non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; China; Diclofenac; Humans | 2003 |
Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Bu | 2004 |
Nabumetone: a clinical appraisal.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Trials as Topic; | 1994 |
A review of selected newer nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Trials as Topic; | 1994 |
Nabumetone: a "nonacidic" nonsteroidal antiinflammatory drug.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Drug Interactions; Humans | 1993 |
[Nabumetone, a new nonsteroidal antiinflammatory agent: clinical prospects].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Drug Evaluation; | 1996 |
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg | 1999 |
Efficacy and improved safety--a new anti-arthritic agent.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Controlled C | 1991 |
Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Humans; Nabumetone; Osteo | 1992 |
Nabumetone (Relifex)--another NSAID.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Humans; Nabumetone; Osteo | 1988 |
Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; | 1988 |
37 trials available for nabumetone and Arthritis, Degenerative
| Article | Year |
|---|---|
Nabumetone: a double-blind study in osteoarthrosis.
Topics: Aged; Anti-Inflammatory Agents; Butanones; Clinical Trials as Topic; Double-Blind Method; Female; Hu | 1984 |
Efficacy and safety of nabumetone in long-term treatment of osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents; Butanones; Clinical Trials as Topic; Digestive System; Female; Human | 1984 |
Double-blind crossover study of nabumetone versus naproxen in the treatment of osteoarthritis of the knee and hip.
Topics: Anti-Inflammatory Agents; Butanones; Double-Blind Method; Drug Tolerance; Hip Joint; Humans; Knee Jo | 1982 |
Double-blind crossover study of nabumetone versus naproxen in the treatment of osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents; Butanones; Double-Blind Method; Drug Tolerance; Female; Hip Joint; H | 1982 |
A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Double-Blind Method | 1994 |
A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Endoscopy, Digestive | 1993 |
Randomized double-blind study of nabumetone and piroxicam in the treatment of osteoarthritis in Dutch general practice: efficacy and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Double-Blind Met | 1993 |
Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Diclofenac; | 1993 |
Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; | 1993 |
Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Diclofenac; | 1993 |
A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Diclofenac; Dose | 1995 |
[Peripheral arthritis in family practice].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Double-Blind Method; Family Practic | 1996 |
Health-related quality of life assessments in osteoarthritis during NSAID treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Double-Blind Met | 1996 |
Etodolac (Lodine) in the treatment of osteoarthritis: recent studies.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Double-Blind Method; | 1997 |
[Efficacy and safety of nabumetone in the treatment of knee osteoarthritis: a comparative clinical trial versus aceclofenac. Study Group of Nabumetone for Osteoarthritis of the Knee].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Diclofenac; Female; Humans; Knee Joint; Ma | 1997 |
Renal hemodynamic effects of nabumetone, sulindac, and placebo in patients with osteoarthritis.
Topics: 6-Ketoprostaglandin F1 alpha; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cross-Over Studies | 1999 |
Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Diclofenac; Double-Blind Method; Dr | 1999 |
Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Digestive System; Double-Blind Meth | 2000 |
Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; D | 2001 |
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Disability Evaluation; | 2001 |
Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis.
Topics: Adult; Aged; Aging; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Butanon | 1992 |
Nabumetone compared with indomethacin in the treatment of osteoarthritis in general practice.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Dose-Response Relationship, Drug; Family | 1992 |
A microcomputer-assisted study of nabumetone and slow release diclofenac in osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Delayed-Action P | 1990 |
An overview of the long-term safety experience of nabumetone.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Digestive System; Double-Blind Method; Hum | 1990 |
German drug monitoring studies with nabumetone.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; | 1990 |
Efficacy and safety of nabumetone in 5,421 patients with osteoarthritis of the hip and/or knee joints. A subgroup evaluation of an outpatient study involving 18,047 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Dose | 1990 |
Analgesic activity of nabumetone versus naproxen in acute exacerbation of osteoarthritis. A short term study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Drug Evaluation; Female; Humans; Male; Nabumeton | 1990 |
Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; | 1988 |
A 6-month, double-blind study comparing nabumetone to naproxen in the treatment of osteoarthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Body Weight; Butanones; Clinic | 1987 |
Review of the experience with nabumetone in clinical trials outside of the United States.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Athletic Injuries; Butanones; | 1987 |
Safety evaluation of nabumetone in United States clinical trials.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Tri | 1987 |
Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Tri | 1987 |
Nabumetone therapy of osteoarthritis. A six-week, placebo-controlled study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials as Topic; Double-Bl | 1987 |
Results of a six-month study comparing the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Clinical Trials as Topic; | 1987 |
Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Clinical Trials as Topic; | 1987 |
Nabumetone versus naproxen in the treatment of osteoarthritis. A six-month trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials as Topic; Double-Bl | 1987 |
Six-month multi-center study comparing nabumetone with naproxen in the treatment of osteoarthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials as Topic; Double-Bl | 1987 |
19 other studies available for nabumetone and Arthritis, Degenerative
| Article | Year |
|---|---|
Risk factors of adverse drug reaction from non-steroidal anti-inflammatory drugs in Shanghai patients with arthropathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheu | 2004 |
[Orthokin as new therapeutic option for orthopedic diseases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Transfusion, Autologous; Butan | 2004 |
Adverse effect of drug-induced emotional problems on work and daily activities. A principal component as an independent predictor of ADRs in Shanghai patients with osteo-arthropathy taking nabumetone.
Topics: Activities of Daily Living; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Emotions; Humans; Lo | 2004 |
Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase Inh | 2006 |
GI bleeding associated with nabumetone.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Gastrointestinal Hemorrhage; Humans; Male; | 1994 |
How much faith can we have in pharmacoeconomic analyses?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials as Topic; Cost-Benefit Analysis; | 1994 |
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T | 2002 |
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials | 2001 |
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials, Phase II as Topic; Clinic | 2002 |
Trends in medication use for osteoarthritis treatment.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Drug Utilization; | 2002 |
The different patterns of blood pressure elevation by rofecoxib and nabumetone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Butanones; Circadian Rhythm; Female; Humans | 2002 |
NSAIDs for the new decade--nabumetone?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Gastrointestinal Hemorrha | 1991 |
The long-term U.S. study--a report on outcome and tolerance.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Trials as | 1991 |
Effect of nabumetone on metabolism of renal arachidonate in humans.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Butanones; Female; Humans; K | 1992 |
Nabumetone--a new NSAID.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Trials as Topic; | 1992 |
[Efficacy and tolerability of nabumetone in the treatment of painful symptomatology of rheumatoid arthritis and osteoarthrosis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Drug Evaluat | 1991 |
[A preliminary study on the tolerability and efficacy of nabumetone in the treatment of acute or chronic and very painful rheumatic diseases].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Drug Tolerance; Female; Humans; Joint Dis | 1990 |
A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anti-Inflammatory Agents, Non-Steroidal; Arthriti | 1989 |
Nabumetone kinetics in the young and elderly.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Humans; Nabumetone; Os | 1987 |